TABLE 2

Baseline characteristics of patients before and after matching for the analysis of annual rate of clinically significant exacerbations and annual rate of exacerbations leading to ED visit or hospitalisation

Baseline characteristics	SIROCCO/CALIMA (before adjustment)^#	MENSA/DREAM (aggregate reported data)	SIROCCO/CALIMA (after adjustment)
Baseline characteristics	Benralizumab Q8, placebo	Mepolizumab 75 mg IV, mepolizumab 100 mg SC, placebo	Benralizumab Q8W, placebo
Patients n	959	884	639^¶
Eosinophil count
≥300 cells·µL⁻¹	67.05	52.45	52.75
<300 cells·µL⁻¹	32.95	47.55	47.25
Maintenance oral corticosteroid use
Yes	15.22	26.58⁺	30.18
No use	84.78	73.42⁺	69.82
IgE count
<30 IU·mL⁻¹	11.55	13.29	14.66
≥30–≤700 IU·mL⁻¹	71.19	70.35	70.02
>700 IU·mL⁻¹	17.27	16.35	15.32
Sex
Male	36.60	40.05	39.2
Female	63.40	59.95	60.8
Exacerbations in the previous year
2	61.63	42.99	42.69
>2	38.38	56.79	57.31
Nasal polyps
No	81.33	86.83	83.44
Yes	18.67	13.17	16.56
BMI mean±sd kg·m⁻²	29.89±6.27	27.98±5.912	28.37±6.13

Data are presented as %, unless otherwise stated. ED: emergency department; Q8W: every 8 weeks (first three doses every 4 weeks); IV: intravenous; SC: subcutaneous; BMI: body mass index. ^#: includes only patients receiving fluticasone propionate ≥880 µg·day⁻¹; ^¶: effective sample size; ⁺: data extracted from publications rather than clinical study reports.